Best Practice & Research Clinical Haematology
Volume 20, Issue 2 , Pages 231-246 , June 2007

Risk assessment in haematopoietic stem cell transplantation: The liver as a risk factor

  • Enric Carreras, MD, PhD (Senior Consultant, and Head, BMT Unit Hospital Clinic Barcelona)

      Affiliations

    • Corresponding Author InformationTel.: +34 93 227 54 28; Fax: +34 93 227 54 84.

References 

  1. Blume KG, Amylon MD. The evaluation and counselling of candidates for hematopoietic cell transplantation. In:  Blume KG,  Forman SJ,  Appelbaum F editor. Thomas' Hematopoietic Cell Transplantation. Malden, MA: Blackwell Sciences; 2004;p. 449–462
  2. Confer DL. Hematopoietic cell donor. In:  Blume KG,  Forman SJ,  Appelbaum F editor. Thomas' Hematopoietic Cell Transplantation. Malden, MA: Blackwell Sciences; 2004;p. 538–549
  3. Strasser SI, McDonald GB. Gastrointestinal and hepatic complications. In:  Blume KG,  Forman SJ,  Appelbaum F editor. Thomas' Hematopoietic Cell Transplantation. Malden, MA: Blackwell Sciences; 2004;p. 769–809
  4. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood. 1998;92:3599–3604
  5. Socie G, Salooja N, Cohen A, et al. Late Effects Working Party of the European Study Group for Blood and Marrow Transplantation. Non-malignant late effects after allogeneic stem cell transplantation. Blood. 2003;101:3373–3385
  6. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100:17–21
  7. Peffault de Latour R, Levy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004;103:1618–1624
  8. Gratwohl A, Speck B, Wenk M, et al. Cyclosporine in human bone marrow transplantation. Serum concentration, graft-versus-host disease, and nephrotoxicity. Transplantation. 1983;36:40–44
  9. McIntyre N. Symptoms and signs of liver disease. In:  Bircher J,  Benhamou JP,  McIntyre N,  Rizzetto M,  Rodés J editor. Oxford Textbook of Clinical Hepatology. 2nd edn.. Oxford: Oxford University Press; 1999;p. 479–499
  10. Van deursen C, Delaere K, Tenkate J. Hemochromatosis and sexual dysfunction. International Journal of Impotence Research. 2003;15:430–432
  11. Prieto JM, Saez R, Carreras E, et al. Physical and psychosocial functioning of 117 survivors of bone marrow transplantation. Bone Marrow Transplantation. 1996;17:1133–1142
  12. Rosalki SB, McIntyre N. Biochemical investigations in the management of liver disease. In:  Bircher J,  Benhamou JP,  McIntyre N,  Rizzetto M,  Rodés J editor. Oxford Textbook of Clinical Hepatology. 2nd edn.. Oxford: Oxford University Press; 1999;p. 503–521
  13. Gordon LI, Brown SG, Tallman MS, et al. Sequential changes in serum iron and ferritin in patients undergoing high-dose chemotherapy and radiation with autologous bone marrow transplantation: possible implications for treatment related toxicity. Free Radical Biology & Medicine. 1995;18:383–389
  14. Foerder CA, Tobin AA, McDonald GB, et al. Bleomycin-detectable iron in plasma of bone-marrow transplant patients –its correlation to liver injury. Transplantation. 1992;54:1120–1123
  15. Muretto P, Del Fiasco S, Angelucci E, et al. Bone marrow transplantation in thalassemia: modifications of hepatic iron overload and associated lesions after long-term engrafting. Liver. 1994;14:14–24
  16. Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. The New England Journal of Medicine. 1993;329:840–844
  17. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology. 1997;25:759–768
  18. Strasser SI, Kowdley KV, Sale GE, et al. Iron overload in bone marrow transplant recipients. Bone Marrow Transplantation. 1998;22:167–173
  19. Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplantation. 1999;24:307–312
  20. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107:3436–3441
  21. Tibballs J, Watkinson AF, Menu Y. Imaging of the liver and biliary tract. In:  Bircher J,  Benhamou JP,  McIntyre N,  Rizzetto M,  Rodés J editor. Oxford Textbook of Clinical Hepatology. 2nd edn. Oxford: Oxford University Press; 1999;p. 549–578
  22. Kawamoto M, Mizuguchi T, Katsuramaki T, et al. Assessment of liver fibrosis by a non-invasive method of transient elastography and biochemical markers. World Journal of Gastroenterology. 2006;12:4325–4330
  23. Verveer C, De Knegt RJ. Non-invasive measurement of liver fibrosis: Application of the FibroScan(R) in hepatology. Scandinavian Journal of Gastroenterology. Supplement. 2006;243:85–88
  24. Strasser SI, McDonald GB. Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management. Blood. 1999;93:1127–1136
  25. Carreras E, Grañena A, Navasa M, et al. Transjugular liver biopsy in BMT. Bone Marrow Transplantation. 1993;11:21–26
  26. Dodd RY. Current safety of the blood supply in the United States. International Journal of Hematology. 2004;80:301–305
  27. Locasciulli A, Alberti A, de Bock R, et al. Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe: a survey from the European Bone Marrow Transplantation (EBMT) Group-Infectious Diseases Working Party. Bone Marrow Transplantation. 1994;14:833–837
  28. Idilman R, Ustun C, Karayalcin S, et al. Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation. Clinical Transplantation. 2003;17:438–443
  29. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43(supplement 1):S173–S181
  30. Rovira R, Carreras E. Otras infecciones víricas. In:  Carreras E editors. Manual de Trasplante Hematopoyético. 3rd edn.. Barcelona: Editorial Antares; 2004;p. 401–408
  31. Locasciulli A, Alberti A, Bandini G, et al. Allogeneic bone marrow transplantation from HBsAg+ donors: a multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood. 1995;86:3236–3240
  32. Locasciulli A, Bacigalupo A, Van Lint MT, et al. Hepatitis B virus (HBV) infection and liver disease after allogeneic bone marrow transplantation: a report of 30 cases. Bone Marrow Transplantation. 1990;6:25–29
  33. Lau GK, Liang R, Chiu EK, et al. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplantation. 1997;19:795–799
  34. Locasciulli A, Bruno B, Alessandrino EP, et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplantation. 2003;31:295–300
  35. Lau GK, Lie AK, Kwong YL, et al. A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation. Blood. 2000;96:452–458
  36. Chan PC, Chen HL, Kong MS, et al. Factors affecting the mortality of pediatric fulminant hepatic failure in relation to hepatitis B virus infection. Journal of Gastroenterology and Hepatology. 2005;20:1223–1227
  37. Hsiao LT, Chiou TJ, Liu JH, et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biology of Blood and Marrow Transplantation. 2006;12:84–94
  38. Hui CK, Lie A, Au WY, et al. Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. American Journal of Transplantation. 2005;5:1437–1445
  39. Lin PC, Poh SB, Lee MY, et al. Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. International Journal of Hematology. 2005;81:349–351
  40. McIvor C, Morton J, Bryant A, et al. Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation. Annals of Internal Medicine. 1994;121:274–275
  41. Tedder RS, Zuckerman MA, Goldstone AH, et al. Hepatitis B transmission from contaminated cryopreservation tank. Lancet. 1995;346:137–140
  42. Dhedin N, Douvin C, Kuentz M, et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation. 1998;66:616–619
  43. Onozawa M, Hashino S, Izumiyama K, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation. 2005;79:616–619
  44. Ljungman P, Engelhard D, de la Camara R, et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplantation. 2005;35:737–746
  45. Locasciulli A, Alberti A. Hepatitis C virus serum markers and liver disease in children with leukemia. Leukemia & Lymphoma. 1995;17:245–249
  46. Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology. 1999;29:1893–1899
  47. Frickhofen N, Wiesneth M, Jainta C, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood. 1994;83:1998–2004
  48. Ljungman P, Hagglund H, Lonnqvist B, et al. Hepatitis C virus as a risk factor for the development of veno-occlusive disease of the liver. Blood. 1994;84:1349–1350
  49. Norol F, Roche B, Girardin MF, et al. Hepatitis C virus infection and allogeneic bone marrow transplantation. Transplantation. 1994;57:393–397
  50. Locasciulli A, Bacigalupo A, VanLint MT, et al. Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplantation. 1995;16:407–411
  51. Fujii Y, Kaku K, Tanaka M, et al. Hepatitis C virus infection and liver disease after allogeneic bone marrow transplantation. Bone Marrow Transplantation. 1994;13:523–526
  52. Maruta A, Kanamori H, Fukawa H, et al. Liver function tests of recipients with hepatitis C virus infection after bone marrow transplantation. Bone Marrow Transplantation. 1994;13:417–422
  53. Ljungman P, Johansson N, Aschan J, et al. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood. 1995;86:1614–1618
  54. Shulman HM, Sharma P, Amos D, et al. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology. 1988;8:463–470
  55. Kaji K, Nakanuma Y, Sasaki M, et al. Hepatitic bile duct injuries in chronic hepatitis C: histopathologic and immunohistochemical studies. Modern Pathology. 1994;7:937–945
  56. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Seminars in Liver Disease. 1995;15:70–81
  57. Strasser SI, Sullivan KM, Myerson D, et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood. 1999;93:3259–3266
  58. Ribas A, Gale RP. Should people with hepatitis C virus infection receive a bone marrow transplant?. Bone Marrow Transplantation. 1997;19:97–99
  59. Ljungman P, Andersson J, Aschan J, et al. Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation. Clinical Infectious Diseases. 1996;23:167–169
  60. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. Journal of Hepatology. 1996;25:591–598
  61. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 1995;123:897–903
  62. Carlsson T, Reichard O, Norkrans G, et al. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. Journal of Viral Hepatitis. 2005;12:473–480
  63. Ferenci P, Formann E, Laferl H, et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. Journal of Hepatology. 2006;44:275–282
  64. de Latour RP, Asselah T, Levy V, et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplantation. 2005;36:709–713
  65. Chen PM, Liu JH, Fan FS, et al. Liver disease after bone marrow transplantation–the Taiwan experience. Transplantation. 1995;59:1139–1143
  66. Ustun C, Koc H, Karayalcin S, et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplantation. 1997;20:289–296
  67. Main J, Brown JL, Howells C, et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. Journal of Viral Hepatitis. 1996;3:211–215
  68. Yao G, Wang B, Cui Z, et al. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection. Chinese Medical Journal. 1999;112:387–391
  69. Chiba T, Yokosuka O, Goto S, et al. Successful clearance of hepatitis B virus after allogeneic stem cell transplantation: beneficial combination of adoptive immunity transfer and lamivudine. European Journal of Haematology. 2003;71:220–223
  70. Mason AL, Xu L, Guo L, et al. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology. 1998;27:1736–1742
  71. Lau GK, Liang R, Lee CK, et al. Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive. The Journal of Infectious Diseases. 1998;178:1585–1591
  72. Shuhart MC, Myerson D, Childs BH, et al. Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course. Blood. 1994;84:3229–3235

PII: S1521-6926(06)00079-X

doi: 10.1016/j.beha.2006.10.010

Best Practice & Research Clinical Haematology
Volume 20, Issue 2 , Pages 231-246 , June 2007

Article Tools